cigna coverage for glp-1 Weight loss drugs' high costs prompt to cut employee health plan Cigna will stop covering GLP-1
Description
Novo Nordisk, EVOKE and EVOKE+ phase 3 trial topline results, Alzheimers Association statement, 2025
All participants underwent continuous glucose monitoring (CGM) for three consecutive days, then TIR and glycemic variability (GV) parameters were evaluated
The order addresses issues including cost representations, claims substantiation, review/testimonial integrity, and subscription cancellation and refund practices
Author: Prasenjit Naskar - M.Sc.
An integrated approach providing wraparound care is needed to address the increase in GLP-1 use and to curb rising costs for many employers and health plans.
